OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
00542055

Cosmo Chemical Co Ltd

Commodity ChemicalsVerified

The company's capital structure is highly leveraged, with a debt-to-equity ratio of 1.8, indicating significant reliance on debt financing. Despite a negative net income of KRW 30.34 billion, the company maintains a positive operating cash flow of KRW 121.74 billion, which partially offsets the free cash flow deficit of KRW 58.74 billion. The liquidity position is rated as medium, with a current ratio of 0.61, suggesting limited short-term liquidity to cover current liabilities. Profitability metrics are weak, with a return on equity of -13.8% and a return on assets of -2.6%, both significantly below the industry median for commodity chemicals. The company's operating income is negative at KRW 16.45 billion, and its gross profit margin is only 4.0%, indicating cost pressures and pricing challenges. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification increases exposure to regional economic and regulatory risks. The company's growth trajectory is uncertain, with no specific revenue growth or decline percentages provided in the outlook. However, the negative net income and operating income suggest a challenging operating environment. The company's capital expenditures of KRW 55.10 billion indicate ongoing investment, but the free cash flow deficit suggests that these investments are not yet generating positive returns. The company's risk profile is elevated, with a medium liquidity risk and a negative net cash position after subtracting total debt. The dilution risk is rated as low, with no significant dilution events reported in the recent financial data. The company's financial leverage and negative earnings increase the risk of further debt financing, which could lead to additional dilution. Recent events include the publication of the latest financial statements, which show a significant decline in profitability and a negative net income. No recent filings or transcripts provide additional context on the company's strategic direction or operational performance.

30-day price · 005420(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyCosmo Chemical Co Ltd
Ticker005420.KS
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustryCommodity Chemicals
AI analysis

Business. Cosmo Chemical Co Ltd is a South Korean company engaged in the production and sale of commodity chemicals, primarily serving the basic materials sector.

Classification. Cosmo Chemical Co Ltd is classified under the Basic Materials economic sector, Chemicals business sector, and Commodity Chemicals industry, with a classification confidence of 0.92.

The company's capital structure is highly leveraged, with a debt-to-equity ratio of 1.8, indicating significant reliance on debt financing. Despite a negative net income of KRW 30.34 billion, the company maintains a positive operating cash flow of KRW 121.74 billion, which partially offsets the free cash flow deficit of KRW 58.74 billion. The liquidity position is rated as medium, with a current ratio of 0.61, suggesting limited short-term liquidity to cover current liabilities. Profitability metrics are weak, with a return on equity of -13.8% and a return on assets of -2.6%, both significantly below the industry median for commodity chemicals. The company's operating income is negative at KRW 16.45 billion, and its gross profit margin is only 4.0%, indicating cost pressures and pricing challenges. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification increases exposure to regional economic and regulatory risks. The company's growth trajectory is uncertain, with no specific revenue growth or decline percentages provided in the outlook. However, the negative net income and operating income suggest a challenging operating environment. The company's capital expenditures of KRW 55.10 billion indicate ongoing investment, but the free cash flow deficit suggests that these investments are not yet generating positive returns. The company's risk profile is elevated, with a medium liquidity risk and a negative net cash position after subtracting total debt. The dilution risk is rated as low, with no significant dilution events reported in the recent financial data. The company's financial leverage and negative earnings increase the risk of further debt financing, which could lead to additional dilution. Recent events include the publication of the latest financial statements, which show a significant decline in profitability and a negative net income. No recent filings or transcripts provide additional context on the company's strategic direction or operational performance.
Key takeaways
  • Cosmo Chemical Co Ltd is highly leveraged, with a debt-to-equity ratio of 1.8, indicating significant financial risk.
  • The company's profitability is weak, with a return on equity of -13.8% and a return on assets of -2.6%.
  • The company's liquidity position is medium, with a current ratio of 0.61, suggesting limited short-term liquidity.
  • The company's revenue is concentrated in a single business segment, increasing exposure to regional and industry-specific risks.
  • The company's growth trajectory is uncertain, with no specific revenue growth or decline percentages provided in the outlook.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyKRW
Revenue$664.16B
Gross profit$26.58B
Operating income-$16.45B
Net income-$30.34B
R&D
SG&A
D&A
SBC
Operating cash flow$121.74B
CapEx-$55.10B
Free cash flow-$58.74B
Total assets$1.17T
Total liabilities$948.54B
Total equity$219.83B
Cash & equivalents$42.44B
Long-term debt$395.23B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$664.16B-$16.45B-$30.34B-$58.74B
FY-1$749.28B-$30.22B-$64.68B-$221.56B
FY-2$798.98B$3.43B-$26.83B-$168.64B
FY-3$718.19B$41.31B$11.24B$14.78B
FY-4$512.61B$32.55B$10.89B$1.06B
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$1.17T$219.83B$42.44B
FY-1$1.20T$229.06B$12.39B
FY-2$1.09T$294.53B$67.73B
FY-3$807.86B$213.90B$38.59B
FY-4$681.34B$152.88B$21.60B
PeriodOCFCapExFCFSBC
FY0$121.74B-$55.10B-$58.74B
FY-1-$27.72B-$199.89B-$221.56B
FY-2-$44.95B-$185.66B-$168.64B
FY-3-$1.49B-$42.68B$14.78B
FY-4$30.39B-$46.44B$1.06B
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0$173.49B-$7.73B-$13.99B-$24.59B
FQ-1$152.00B-$4.92B-$8.67B-$17.85B
FQ-2$177.06B-$4.73B-$5.72B-$7.30B
FQ-3$161.60B$944.8M-$1.96B-$9.00B
FQ-4$189.33B-$34.80B-$46.92B-$66.73B
FQ-5$166.68B$1.14B-$5.66B-$17.67B
FQ-6$233.53B$4.21B-$5.43B-$53.70B
FQ-7$159.73B-$450.7M-$6.68B-$83.45B
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0$1.17T$219.83B$42.44B
FQ-1$1.18T$210.41B$40.09B
FQ-2$1.18T$219.07B$15.35B
FQ-3$1.18T$227.10B$45.87B
FQ-4$1.20T$229.06B$12.39B
FQ-5$1.18T$277.72B$8.18B
FQ-6$1.17T$283.55B$15.16B
FQ-7$1.10T$288.09B$4.86B
PeriodOCFCapExFCFSBC
FQ0$121.74B-$55.10B-$24.59B
FQ-1$71.74B-$38.99B-$17.85B
FQ-2$41.01B-$24.91B-$7.30B
FQ-3$60.53B-$14.99B-$9.00B
FQ-4-$27.72B-$199.89B-$66.73B
FQ-5$36.90B-$171.86B-$17.67B
FQ-6$49.11B-$146.81B-$53.70B
FQ-7$20.30B-$87.80B-$83.45B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$219.83B
Net cash-$352.80B
Current ratio0.6
Debt/Equity1.8
ROA-2.6%
ROE-13.8%
Cash conversion-4.0%
CapEx/Revenue-8.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 11 companies
Metric005420Activity
Op margin-2.5%0.4% medp25 -8.0% · p75 16.0%below median
Net margin-4.6%2.3% medp25 -11.6% · p75 11.8%below median
Gross margin4.0%20.8% medp25 14.9% · p75 24.0%bottom quartile
R&D / revenue1.1% medp25 0.5% · p75 1.3%
CapEx / revenue-8.3%6.2% medp25 5.4% · p75 10.2%bottom quartile
Debt / equity180.0%59.0% medp25 54.9% · p75 72.9%top quartile
Source: analysis-pipeline (hybrid)Generated: 2026-05-18 01:16 UTCJob: 04e3c9a2